Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current


Myriad Genetics Celebrates One Million SneakPeek Results Shared With Expectant Parents

Author: Benzinga Newsdesk | November 20, 2023 05:19pm

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test. Since 2015, SneakPeek has been providing expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy.


SneakPeek is 99% accurate1 and is one of the earliest ways to learn the baby's predicted fetal sex. Customers can choose to take the test at home or have their blood collected at a local clinic. The at-home test kit includes the innovative SneakPeek Snap® device, which is placed on the user's upper arm and a button is pressed to collect the blood sample. Samples are mailed to the SneakPeek laboratory and test results are shared as early as the same day the sample is received through email.

"When my wife and I were expecting our first baby, we were curious to learn whether we were having a boy or a girl. As a bioengineer who had helped develop other prenatal tests, it got me thinking that there had to be a way to make fetal sex prediction simple, affordable and more accessible so people could do the test in the comfort of their own home," said Chris Jacob, senior vice president and general manager, Myriad Genetics. "From there, SneakPeek was born and since then we have served one million expectant parents, allowing them to easily experience that magical moment of learning the sex of their baby for the first time."

In 2022, Myriad acquired Gateway Genomics, a personal genomics company and the developer of SneakPeek. With the addition of SneakPeek to the Myriad Genetics portfolio, the company offers a comprehensive suite of reproductive health testing solutions before, during and after pregnancy, which also includes the Prequel® Noninvasive Prenatal Screen, Foresight® Carrier Screen and MyRisk® Hereditary Cancer Test with RiskScore®.

"This momentous occasion represents an exciting step forward in expanding access to fetal sex testing at six weeks," said Melissa Gonzales, president of women's health, Myriad Genetics. "Earlier this year, we also celebrated one million patients being screened with Prequel. The combined synergies from our products are providing more patients with relevant information in a way that is equitable, affordable and easy to use."

1 See www.sneakpeektest.com/publications for supporting scientific studies

Posted In: MYGN